Investment Shastra

Company Shastra: Biocon Ltd.

Biocon, India’s largest biotechnology company, manufactures innovative biopharmaceuticals (medical drugs produced using biotechnology) which cater primarily to high growth areas of diabetology, nephrology, cardiology and oncology. A research-driven company, Biocon has been continuously focusing on bringing out innovative molecules; it launched the world’s first recombinant human insulin ‘Insugen’.

But this focus on research and development has led to somewhat muted growth – especially in profitability – over the years, as compared to other pharmaceutical companies. However, recently, it signed a mega marketing deal worth $ 350 million with the world’s largest drug-maker Pfizer to globally commercialise four of its insulin biosimilar products.

So, what does this deal signal for Biocon’s future?

And, will the company now capitalize on its R&D investments and shift gears in the future?

Biocon, India’s largest biotechnology company, manufactures innovative biopharmaceuticals (medical drugs produced using biotechnology) which cater primarily to high growth areas of diabetology, nephrology, cardiology and oncology. A research-driven company, Biocon has been continuously focusing on bringing out innovative molecules; it launched the world’s first recombinant human insulin ‘Insugen’.

But this focus on research and development has led to somewhat muted growth – especially in profitability – over the years, as compared to other pharmaceutical companies. However, recently, it signed a mega marketing deal worth $ 350 million with the world’s largest drug-maker Pfizer to globally commercialise four of its insulin biosimilar products.

So, what does this deal signal for Biocon’s future?

And, will the company now capitalize on its R&D investments and shift gears in the future?

What’s your Reaction?
+1
0
+1
0
+1
0

Stay Informed: Subscribe to Our Newsletter for Key Updates

Team-MoneyWorks4me

A team of business leaders, equity research analysts & investment counsellors. Started in 2008; experienced in equity research, financial planning and portfolio management. Passionate about providing institutional quality research and advice to Retail Investors in a simple easy-to-understand-and-act manner.

Search

Archives

×